TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.

Saved in:
Bibliographic Details
Title: TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Authors: Mayer, E.L.1 Erica_Mayer@dfci.harvard.edu, Abramson, V.2, Jankowitz, R.3, Falkson, C.4, Marcom, P.K.5, Traina, T.6, Carey, L.7, Rimawi, M.8, Specht, J.9, Miller, K.10, Stearns, V.11, Tung, N.12, Perou, C.7, Richardson, A.L.11, Componeschi, K.1, Trippa, L.1, Tan-Wasielewski, Z.1, Timms, K.13, Krop, I.1, Wolff, A.C.11
Source: Annals of Oncology. Nov2020, Vol. 31 Issue 11, p1518-1525. 8p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2020.08.2064